drugset / Trial / NCT01518062

Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome

NCT01518062

Phase 4 Completed 65 enrolled Novo Nordisk A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in Europe. The aim of this trial is to assess whether increasing doses of somatropin (Norditropin®) can maintain the initial increase in height velocity and improve final height. This trial has two trial periods, a main period of 4 years and an extension period until final height is reached.

Timeline

Start
1989-11
Primary completion
2003-09
Completion
2003-09

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Somatropin Protein / enzyme biologic 4 iu Subcutaneous
Subject Somatropin Protein / enzyme biologic 6 iu Subcutaneous
Subject Somatropin Protein / enzyme biologic 8 iu Subcutaneous
Background 17-beta estradiol Unknown 5 ug/kg Oral